AC Immune SA General and Administrative Expenses 2011-2025 | ACIU

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses AC Immune SA

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	17.9 M	11.1 M	9.42 M	7.56 M	6.27 M	4.73 M	2.04 M	2 M	-	-	-

All numbers in CHF currency

Indicator range from annual reports

Maximum	Minimum	Average
17.9 M	2 M	7.63 M

Quarterly General and Administrative Expenses AC Immune SA

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.76 M	2.93 M	3.06 M	2.71 M	3.06 M	2.52 M	2.17 M	2.39 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in CHF currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
3.76 M	2.17 M	2.82 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
ADiTx Therapeutics ADTX	16.3 M	$ 2.49	-11.39 %	$ 32.8 K	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
Abeona Therapeutics ABEO	19 M	$ 4.59	-4.08 %	$ 98.1 M	USA
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Amneal Pharmaceuticals AMRX	476 M	$ 12.12	-1.58 %	$ 3.74 B	USA
Axcella Health AXLA	15.8 M	-	-16.42 %	$ 249 M	USA
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
Armata Pharmaceuticals ARMP	11.6 M	$ 5.37	-20.68 %	$ 194 M	USA
Atreca BCEL	31.5 M	-	-11.76 %	$ 5.79 M	USA
Brainstorm Cell Therapeutics BCLI	7.04 M	-	-2.5 %	$ 5.88 M	USA
argenx SE ARGX	308 M	$ 919.62	2.76 %	$ 25 B	Niderland
Ascendis Pharma A/S ASND	160 M	$ 203.0	-3.72 %	$ 5 B	Danmark
Achieve Life Sciences ACHV	11.4 M	$ 4.64	-0.32 %	$ 92 M	USA
BioDelivery Sciences International BDSI	106 M	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	1.83 B	-	0.49 %	$ 251 B	Cayman-islands
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Alterity Therapeutics Limited ATHE	5.51 M	$ 3.36	2.73 %	$ 8.08 B	Australia
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
Bellerophon Therapeutics BLPH	6.02 M	-	-74.18 %	$ 955 K	USA
BioLineRx Ltd. BLRX	4.31 M	$ 3.29	-1.5 %	$ 908 M	Israel
BioMarin Pharmaceutical BMRN	1.01 B	$ 54.27	-1.38 %	$ 10.3 B	USA
Adaptimmune Therapeutics plc ADAP	73.5 M	-	-15.15 %	$ 60.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Baudax Bio BXRX	24.1 M	-	0.59 %	$ 63 K	USA
AbbVie ABBV	14.8 B	$ 224.99	-0.01 %	$ 398 B	USA
Cara Therapeutics CARA	27.8 M	-	-3.03 %	$ 260 M	USA
CymaBay Therapeutics CBAY	52 M	-	-	$ 3.45 B	USA
ChemoCentryx CCXI	78.9 M	-	-	$ 3.74 B	USA
BioNTech SE BNTX	286 M	$ 96.22	-1.21 %	$ 27.2 B	Germany
Codiak BioSciences CDAK	27.6 M	-	-55.98 %	$ 2.15 M	USA
Adaptive Biotechnologies Corporation ADPT	72.8 M	$ 18.75	-0.48 %	$ 2.76 B	USA
Avid Bioservices CDMO	26 M	-	-	$ 789 M	USA
BioXcel Therapeutics BTAI	34.5 M	$ 1.92	-7.01 %	$ 4.87 M	USA
Biogen BIIB	2.4 B	$ 179.76	1.11 %	$ 26.2 B	USA
Cerevel Therapeutics Holdings CERE	113 M	-	-	$ 7.29 B	USA
ContraFect Corporation CFRX	12.2 M	-	-5.16 %	$ 5.39 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Beam Therapeutics BEAM	112 M	$ 23.52	-2.22 %	$ 1.94 B	USA
AbCellera Biologics ABCL	72.7 M	$ 3.45	-0.72 %	$ 1.02 B	Canada
Cabaletta Bio CABA	19.2 M	$ 2.37	-2.67 %	$ 2.77 M	USA
Clearside Biomedical CLSD	11.9 M	-	-	$ 25.3 M	USA
Celsion Corporation CLSN	7.49 M	-	-6.63 %	$ 13.9 M	USA
Clovis Oncology CLVS	128 M	-	-7.23 %	$ 13 M	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Checkmate Pharmaceuticals CMPI	15.7 M	-	-	$ 231 M	USA
Chimerix CMRX	24.6 M	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	22.5 M	-	-	$ 401 M	USA